TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Novakand Pharma AB
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
9
|
695
|
503 |
| Financial expenses |
0
|
87
|
413 |
| Earnings before taxes |
-28,944
|
-43,584
|
-35,072 |
| EBITDA |
-29,980
|
-43,687
|
-34,463 |
| Total assets |
43,456
|
44,091
|
80,681 |
| Current assets |
31,765
|
32,000
|
66,483 |
| Current liabilities |
2,995
|
12,075
|
9,239 |
| Equity capital |
40,461
|
32,015
|
71,442 |
| - share capital |
7,649
|
5,320
|
44,286 |
| Employees (average) |
5
|
4
|
8 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
93.1%
|
72.6%
|
88.5% |
| Turnover per employee |
2
|
174
|
63 |
| Profit as a percentage of turnover |
-321600%
|
-6271.1%
|
-6972.6% |
| Return on assets (ROA) |
-66.6%
|
-98.7%
|
-43.0% |
| Current ratio |
1060.6%
|
265.0%
|
719.6% |
| Return on equity (ROE) |
-71.5%
|
-136.1%
|
-49.1% |
| Change turnover |
-663
|
189
|
-635 |
| Change turnover % |
-99%
|
37%
|
-56% |
| Chg. No. of employees |
1
|
-4
|
0 |
| Chg. No. of employees % |
25%
|
-50%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.